|
Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. |
|
|
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; Genmab; Roche/Genentech; Seagen |
Research Funding - Genentech; Genmab; Roche |
Travel, Accommodations, Expenses - Genmab |
|
|
Consulting or Advisory Role - Abbvie; Genmab; Janssen; Kite, a Gilead company |
Speakers' Bureau - Abbvie; Janssen |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca/Merck; Genmab; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - ADC Therapeutics; Epizyme; Seagen |
Research Funding - Bristol-Myers Squibb; Genentech; Kite/Gilead; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; Genmab; Janssen; Kite, a Gilead Company; Kyowa Kirin; Lilly O.; Roche; Takeda |
Speakers' Bureau - AbbVie; AstraZeneca; Bristol-Myers Squibb; Janssen; Kite, a Gilead Company; Roche; Takeda |
Research Funding - Pfizer |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
|
|
|
|
|
|
Research Funding - Genmab |
|
|
Consulting or Advisory Role - Gilead Sciences; Janssen-Cilag; MorphoSys; Roche; Takeda |
Research Funding - Dr. Reddy's (Inst); Genmab (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; Roche; Takeda |